Back to News
Market Impact: 0.35
Milestone Gets China Approval For Etripamil Nasal Spray
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
Milestone Pharmaceuticals said China’s National Medical Products Administration approved etripamil nasal spray for adults with paroxysmal supraventricular tachycardia (PSVT). The drug is marketed in the U.S. as CARDAMYST, marking a meaningful regulatory milestone that should support international commercialization prospects.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
MIST0.70
More News
- Bending Spoons wants to revive software castoffs. Berkshire is backing the plan
- AI rapidly improving, could vastly boost U.S. GDP, Anthropic's Clark tells policymakers
- ‘How many canaries have we killed in the coal mine?’ — Wall Street debates if the latest AI bubble warnings are another head fake or the real thing
- Tunisia’s economic crisis deepens as the promise of a better life fades
- States sue OpenAI, saying it gives life to ‘cyberhacking agents’ while ChatGPT hurts children and deceives adults
- Mark Carney makes closing argument to Alberta against path to independence from Canada: outsiders ‘are working to break us so they can own us. Never’